ERBB2 and non-small cell lung carcinoma: The largest research cohort of more than 8000 lung adenocarcinoma samples to date reported the detection of 0.15% (15/8551) of HER2 TMD mutations at amino acid residues V659 or G660 in NSCLC, including p.V659E, p.V659D, p.G660D, and p.G660R, along with other non-V659/G660 TMD mutations, including p.V664F, p.V665M, and p.I675M [7].